Trastuzumab or Lapatinib with Neoadjuvant Chemotherapy in the Management of Previously Untreated HER2-Positive Primary Breast Cancer
OVERVIEW OF ACTIVITY

The annual San Antonio Breast Cancer Symposium (SABCS) is unmatched in its significance with regard to the advancement of breast cancer treatment. It is targeted by many members of the clinical research community as the optimal forum in which to unveil new clinical data. This creates an environment each year in which published results from a plethora of ongoing clinical trials lead to the emergence of many new therapeutic agents and changes in the indications for existing treatments across all breast cancer subtypes. In order to offer optimal patient care — including the option of clinical trial participation — the practicing medical oncologist must be well informed of the rapidly evolving data sets in breast cancer. To bridge the gap between research and patient care, this CME activity will deliver a serial review of the most important emerging data sets from the latest SABCS meeting, including expert perspectives on how these new evidence-based concepts can be applied to routine clinical care. This activity will assist medical oncologists and other cancer clinicians in the formulation of optimal clinical management strategies for breast cancer.

LEARNING OBJECTIVES

- Apply the results of new research when recommending neoadjuvant chemotherapy with anti-HER2 treatment to patients with untreated HER2-positive primary breast cancer.
- Recognize the contribution of agent-specific toxicities to the rate of overall compliance with neoadjuvant anti-HER2 therapy.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this educational activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains slides and edited commentary. To receive credit, the participant should review the slide presentation, read the commentary and complete the Educational Assessment and Credit Form located at CME.ResearchToPractice.com.

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

Michael Untch, MD, PhD  
Head of the Clinic for Gynecology  
Gynecologic Oncology and Obstetrics  
Head of the Breast Cancer Center  
HELIOS Klinikum Berlin-Buch  
Academic Hospital of the University Charité  
Berlin, Germany  
No real or apparent conflicts of interest to disclose.

EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience Inc, a wholly owned subsidiary of Celgene Corporation, Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Lilly USA LLC, Millennium Pharmaceuticals Inc, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi-Aventis and Seattle Genetics.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This program is supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Genomic Health Inc, Novartis Pharmaceuticals Corporation and Sanofi-Aventis.

Last review date: January 2011  
Expiration date: January 2012
To go directly to slides and commentary, click here.

Sometimes the cavernous San Antonio conference hall can be so devoid of attendees that you feel like you could throw a Frisbee® and not hit anyone. But on Friday, December 10, 2010 at 9 AM, even the spillover video simulcast section was standing room only. The occasion was the presentation of three highly anticipated neoadjuvant trials for patients with HER2-positive tumors. To begin this memorable session, Duke’s Neil Spector gave a superb review of anti-HER2 treatment, which he ended with a photo of himself wired up in a hospital gown taken shortly after a heart transplant. (He implored the audience to sign their organ donor cards.) Eric Winer finished things off with an enlightening and thought-provoking follow-up discussion that he told me had him up until 3 AM the night before changing slides. In between, there was plenty to warrant the massive crowd.

To start off this series of eight weekly reports from San Antonio, here’s the bottom line on these historic neoadjuvant HER2 data sets.

1. **German GeparQuinto study: More path CRs with trastuzumab/chemo than lapatinib/chemo**

   In the first reported head-to-head comparison of these two commonly used anti-HER2 agents, Michael Untch demonstrated that the antibody won out over the TKI with a pCR rate (in breast and nodes) of 31.3 percent versus 21.7 percent. A second study reported at SABCS (see below) also showed an advantage to trastuzumab over lapatinib but was not considered statistically significant. Although it may not matter in the long run, much debate has focused on whether this interesting finding is related to an inherent difference in the antitumor efficacy of these agents or the fact that some patients randomly assigned to lapatinib ended up receiving less drug as a result of discontinuation of therapy due to toxicity.

2. **Neo-ALTTO trial: More pCRs with chemo/trastuzumab/lapatinib than with chemo plus either anti-HER2 agent alone**

   In a parallel trial design to the ongoing 8,000-plus-patient international adjuvant trial, this much-awaited neoadjuvant study evaluated chemo with trastuzumab, lapatinib or the combination, and as reported by José Baselga, the dual anti-HER2 arm doubled the pCR rate to 46.9 percent. Although few, if any, investigators are suggesting this approach outside a protocol setting, perhaps this is a first glimpse at where we’ll end up in the next few years.
3. **NEOSPHERE study: Chemo/trastuzumab versus chemo/pertuzumab versus chemo/trastuzumab/pertuzumab versus trastuzumab/pertuzumab**

Luca Gianni (protégé of the legendary Gianni Bonadonna) surprised the multitudes with this study that demonstrated the best pCR rate (39.3 percent) when both antibodies were combined with chemo. However, he also reported an 11.2 percent pCR rate when pertuzumab and trastuzumab were used together without chemo. Pertuzumab — a yet-unavailable agent that inhibits HER2 dimerization — is about to be studied in the adjuvant setting, adding even more hope and potential for the future.

Of course, it will be some time before we know how these neoadjuvant strategies pan out in the long term, but in another important and encouraging paper by the Germans ([the TECHNO trial](#)), pCR after neoadjuvant trastuzumab/chemo was highly correlated with longer-term disease-free and overall survival. If that finding holds true, then SABCS 2010 will forever be remembered as a harbinger of what is to come in the management of HER2-positive disease.

Next up in this series: The big disappointment of San Antonio — the AZURE trial demonstrates no adjuvant benefit with zoledronic acid.

Neil Love, MD  
**Research To Practice**  
Miami, Florida
Trastuzumab or Lapatinib with Neoadjuvant Chemotherapy in the Management of Previously Untreated HER2-Positive Primary Breast Cancer

Presentation discussed in this issue


Slides from a presentation at SABCS 2010 and transcribed comments from a recent interview with Michael Untch, MD, PhD (12/11/10)

Lapatinib versus Trastuzumab in Combination with Neoadjuvant Anthracycline-Taxane-Based Chemotherapy: Primary Efficacy Endpoint Analysis of the GEPARQUINTO Study (GBG 44)

Untch M et al.
Proc SABCS 2010; Abstract S3-1.
Objectives

- Primary: Pathological CR rates
- Secondary:
  - Pathological CR rates with alternate definitions of pathological CR
  - Breast conservation rate
  - Compliance and toxicity
  - Efficacy in stratified risk groups
  - Disease-free and overall survival

Untch M et al. Proc SABCS 2010;Abstract S3-1.

Eligibility

- Untreated primary breast carcinoma
- HER2-positive by local pathology (IHC score 3+ or FISH+)
- Tumor stages:
  - cT4 or cT3
  - cT2 if HR- or cN+
  - cT1 if HR- or if SLN+
- Breast lesion ≥ 2 cm by palpation or ≥ 1 cm by ultrasound
- No metastasis
- Normal organ function
- Left ventricular ejection fraction ≥ 55%

Untch M et al. Proc SABCS 2010;Abstract S3-1.
Study Schema

Core Biopsy
N = 620

T₁ + EC²-Doc³ → Surgery → T₆ x 6 months

L₄ + EC²-Doc⁵ → Surgery → T₆ x 12 months

1 Trastuzumab (T) 6 mg/kg q3wk x 8 (initial loading dose 8 mg/kg)
2 Epirubicin (E) 90 mg/m² and cyclophosphamide (C) 600 mg/m² q3wk x 4
3 Docetaxel (Doc) 100 mg/m² q3wk x 4
4 Lapatinib (L) 1,000-1,250 mg PO QD
5 Doc 100 mg/m² q3wk (with G-CSF support) x 4
6 T 6 mg/kg q3wk

Untch M et al. Proc SABCS 2010;Abstract S3-1.

Efficacy Results

<table>
<thead>
<tr>
<th>Pathological CR (no invasive or noninvasive residual in breast and nodes based on central pathology report review)</th>
<th>T + EC-Doc</th>
<th>L + EC-Doc</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>31.3%</td>
<td>21.7%</td>
<td>&lt; 0.05</td>
<td></td>
</tr>
</tbody>
</table>

Pathological CR (no invasive residual in breast and nodes according to other definitions)

<table>
<thead>
<tr>
<th>Pathological CR (no invasive residual in breast only according to other definitions)</th>
<th>T + EC-Doc</th>
<th>L + EC-Doc</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>50.4%</td>
<td>35.2%</td>
<td>&lt; 0.05</td>
<td></td>
</tr>
</tbody>
</table>

Breast conservation rate

| 65.6% | 56.0% | — |

Untch M et al. Proc SABCS 2010;Abstract S3-1.
### Efficacy Results by Stratification

<table>
<thead>
<tr>
<th></th>
<th>Odds Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall</td>
<td>0.61</td>
</tr>
<tr>
<td>ER/PR-negative</td>
<td>0.63</td>
</tr>
<tr>
<td>ER/PR-positive</td>
<td>0.56</td>
</tr>
<tr>
<td>T1-3 and N0-2</td>
<td>0.54</td>
</tr>
<tr>
<td>T4 or N3</td>
<td>0.97</td>
</tr>
</tbody>
</table>

A lower odds ratio suggests results favorable to T + EC-Doc vs L + EC-Doc.

Untch M et al. *Proc SABCS 2010; Abstract S3-1.*

### Safety and Compliance Results

<table>
<thead>
<tr>
<th></th>
<th>T + EC-Doc</th>
<th>L + EC-Doc</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discontinued chemotherapy +</td>
<td>10%</td>
<td>16%</td>
</tr>
<tr>
<td>anti-HER2 agent</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Discontinued anti-HER2</td>
<td>3.1%</td>
<td>7.0%</td>
</tr>
<tr>
<td>agent only</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serious adverse events</td>
<td>13.5% (T + EC)</td>
<td>17.7% (L + EC)</td>
</tr>
<tr>
<td></td>
<td>14.5% (T + Doc)</td>
<td>15.2% (L + Doc)</td>
</tr>
</tbody>
</table>

Untch M et al. *Proc SABCS 2010; Abstract S3-1.*
Conclusions

- Trastuzumab + EC-docetaxel achieved a significantly higher pathological CR rate in unselected HER2-positive primary breast cancer when compared to the lapatinib combination with the same chemotherapy.
- Efficacy results were consistent in most prespecified subsets, including ER/PR-negative and ER/PR-positive subtypes.
- Compliance of lapatinib with EC-docetaxel was lower than trastuzumab plus EC-docetaxel.
- Results should be seen in the context of other studies like Neo-ALTTO, which uses a higher dose of lapatinib (1,500 mg/d), but a shorter treatment duration.


Investigator Commentary: GEPARQUINTO Neoadjuvant Study (GBG 44)

GEPARQUINTO is the first clinical trial to compare chemotherapy/trastuzumab with chemotherapy/lapatinib. According to NSABP criteria, the pCR was 50 percent with chemotherapy/trastuzumab and 35 percent with chemotherapy/lapatinib, which was unexpectedly lower than was hypothesized at the beginning of this study.

In the intention-to-treat analysis 23 percent of patients in the chemotherapy/lapatinib arm had treatment discontinued due to Grade III and higher diarrhea compared to a 13 percent rate of discontinuation in patients who received chemotherapy/trastuzumab. This was the first time that lapatinib has been administered with anthracyclines and docetaxel, and we had to learn how to cope with the side effects of this combination. We learned that it was necessary to reduce the dose of lapatinib from 1,250 mg to 1,000 mg to avoid the diarrhea, and we also learned to add G-CSF to avoid febrile neutropenia from lapatinib and docetaxel. These are important lessons learned from this trial, and we now discuss with patients which side effects to expect and how to deal with them.

Interview with Michael Untch, MD, PhD, December 11, 2010.